Pharmabiz

US FDA accepts for review Inovio's BLA for INO-3107 to treat adults with recurrent respiratory papillomatosis

Plymouth Meeting, Pennsylvania Tuesday, December 30, 2025, 15:00 Hrs [IST] ...
The Malaysian Reserve

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

The FDA assigned INO-3107 a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026, which is the date by which it intends to take action on the application. The FDA has indicated ...
Gut

CD48 is a novel immune checkpoint on tumour‐associated macrophages in hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today ...
Nature

NAD + protects against EAE by regulating CD4 + T-cell differentiation

The mechanism by which NAD+ alters the systemic immune response is unclear. Here the authors show that NAD+ induces systemic homeostasis and protects against experimental autoimmune encephalomyelitis, ...